Morrison LTR, Anderson B, Brower A, Talbird SE, Buell N, MacDonald PDM, Metz L, Gaudig M, Oriol Mathieu V, Honeycutt AA. Macroeconomic impact of Ebola outbreaks in Sub-Saharan Africa and potential mitigation of GDP loss with prophylactic Ebola vaccination programs. PLoS One. 2023 Apr 11;18(4):e0283721. doi: 10.1371/journal.pone.0283721
Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965
Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293
Puig-Barbera J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, Buiques-Vila A, Martinez-Ubeda S, Sominina A, GIHSN Group. 2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network. PLoS One. 2014 Jun 19;9(6):e100497.
DiBonaventura MD, Yuan Y, Lescrauwaet B, L'italien G, Liu GG, Kamae I, Mauskopf JA. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS One. 2014 Jan 21;9(1):e86070. doi: 10.1371/journal.pone.0086070.
Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured hiv patients in the United States. PLoS One. 2012 Feb 24;7(2):e31591.